In addition, CARs have been generated against a number of surface molecules on solid tumors, including HER2 for colorectal cancer [12], folate receptor-α for ovarian cancer [13], carcinoembryonic antigen (CEA) for colorectal and breast cancer [14], epidermal growth factor receptor variant III (EGFRvIII) for neuroblastoma [15], and prostate-specific membrane antigen (PMSA) for prostate cancer [16]. This evidence concerns the gene CEACAM5 and prostate carcinoma.